✨ Cardior’s lead compound CDR132L is currently in Phase II clinical development for heart failure treatment.
⚙️ Cardior uses a non-coding RNA inhibitor to target microRNA-132, a central regulator of pathological cardiac remodelling processes.
💡 Novo Nordisk plans to initiate a Phase II trial for CDR132L in a chronic heart failure population.
Introduction:
Novo Nordisk, a Danish multinational pharmaceutical company, has announced its plans to acquire German miRNA blocker specialist Cardior Pharmaceuticals for up to €1.025bn. The acquisition includes Cardior’s lead compound CDR132L, which is currently in Phase II clinical development for the treatment of heart failure.
- The takeover agreement includes Cardior’s lead compound CDR132L, which is currently in Phase II clinical development for the treatment of heart failure.
- Cardior uses a non-coding RNA inhibitor (ncRNA inhibitor) to target microRNA-132, a central regulator of pathological cardiac remodelling processes that is overexpressed in patients with heart failure.
- The inhibition of miR-132 by CDR132L leads to normalization.
- Cardior recently received the CE mark for a PCR kit that measures circulating microRNA-132 levels in the blood of patients receiving CDR132L.
- Novo Nordisk plans to initiate a second Phase II trial to investigate CDR132L in a chronic heart failure population with cardiac hypertrophy.
Conclusion:
Novo Nordisk’s acquisition of Cardior Pharmaceuticals and its lead compound CDR132L demonstrates the company’s commitment to expanding its portfolio in the cardiovascular disease field. The use of a non-coding RNA inhibitor to target microRNA-132 shows potential for the normalization of cardiac remodelling processes in patients with heart failure. The completion of the acquisition is expected to happen in the second quarter of 2024.
